Achilles Therapeutics Company Leadership
| ACHL Stock | USD 1.06 0.01 0.93% |
Achilles Therapeutics employs about 204 people. The company is managed by 13 executives with a total tenure of roughly 476 years, averaging almost 36.0 years of service per executive, having 15.69 employees per reported executive. Inspection of Achilles Therapeutics' management performance can provide insight into the company performance.
Achilles |
Achilles Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4422) %, meaning that it created substantial loss on money invested by shareholders. Achilles Therapeutics' management efficiency ratios could be used to measure how well Achilles Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.45. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Achilles Therapeutics' Other Current Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 170.7 M this year, although the value of Other Assets will most likely fall to 0.95.The value of Common Stock Shares Outstanding is expected to slide to about 33 M. Net Loss is expected to rise to about (60.9 M) this year
Achilles Therapeutics Workforce Comparison
Achilles Therapeutics PLC is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 776. Achilles Therapeutics totals roughly 204 in number of employees claiming about 26% of equities under Health Care industry.
Achilles Therapeutics PLC Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Achilles Therapeutics PLC Price Series Summation is a cross summation of Achilles Therapeutics price series and its benchmark/peer.
Achilles Therapeutics Notable Stakeholders
An Achilles Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Achilles Therapeutics often face trade-offs trying to please all of them. Achilles Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Achilles Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sergio Quezada | Founder Officer | Profile | |
| Daniel Hood | General Secretary | Profile | |
| Tariq Ahmed | Executive People | Profile | |
| James Taylor | Chief Officer | Profile | |
| Julia Wilson | Head Communications | Profile | |
| Lee Stern | Vice Communications | Profile | |
| FMEDSCI MD | Founder | Profile | |
| Karl MD | Founder Officer | Profile | |
| Shree Patel | Executive Operations | Profile | |
| Iraj Ali | CEO Director | Profile | |
| BSc FRCPath | Founder | Profile | |
| Edward Samuel | Executive Operations | Profile | |
| Robert Coutts | Chief Officer | Profile |
About Achilles Therapeutics Management Performance
The success or failure of an entity such as Achilles Therapeutics PLC often depends on how effective the management is. Achilles Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Achilles management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Achilles management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.49) | (0.51) |
Achilles Therapeutics Workforce Analysis
Traditionally, organizations such as Achilles Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Achilles Therapeutics within its industry.Achilles Therapeutics Manpower Efficiency
Return on Achilles Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 342.8K | |
| Net Loss Per Executive | 5.4M | |
| Working Capital Per Employee | 630.6K | |
| Working Capital Per Executive | 9.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.